|Articles|January 12, 2011

Are College Students Getting Sicker? No, Diagnoses Change Faster Than People

Author(s)Allen Frances, MD, Allen Frances, MD

The New York Times of Dec 20,2010 carried an alarming story. It seems that during the past decade, college students have suddenly become much more mentally ill.

Array

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Nassir Ghaemi, MD, MPH, Shares What’s Not Exciting in Psychiatry—and What Would Be Exciting

ByS. Nassir Ghaemi, MD, MPH,Heidi Anne Duerr, MPH

May 21st 2025

Use of the PRiSM Diagnostic Instrument in Clinical Practice

ByRonald W. Pies, MD,Mark L. Ruffalo, MSW, DPsa

April 10th 2025

Transforming DSM-6 Development: A Call for Integrated Approaches and Cautious Innovation

BySteven E. Hyler, MD, DLFAPA

February 27th 2025

Do Psychiatric Diagnoses Cause Symptoms?

ByRonald W. Pies, MD,Mark L. Ruffalo, MSW, DPsa

September 4th 2024

Prolonged Grief Disorder: Helping Those With Maladaptive Grief Responses

ByCharles F. Reynolds III, MD

March 29th 2022

Latest CME

Video

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

Register now!

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Are College Students Getting Sicker? No, Diagnoses Change Faster Than People

Newsletter

Related Content

Nassir Ghaemi, MD, MPH, Shares What’s Not Exciting in Psychiatry—and What Would Be Exciting

Use of the PRiSM Diagnostic Instrument in Clinical Practice

Transforming DSM-6 Development: A Call for Integrated Approaches and Cautious Innovation

Do Psychiatric Diagnoses Cause Symptoms?

Prolonged Grief Disorder: Helping Those With Maladaptive Grief Responses

Latest CME

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Southern Florida Psychiatry Conference

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Everything You Need to Know About the Approval of Lumateperone for Major Depressive Disorder

FDA Committee Meets on Generative AI Digital Mental Health Devices

Alixorexton for Treatment of Narcolepsy Type 2: New Positive Phase 2 Data

Lumateperone as an Adjunctive Therapy for MDD: In Conversation With the Primary Investigator

Placebo Response Rates Vary Across Psychiatric Disorders